If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
== History == In China in the 11th and 12th centuries, this technique was used to extract copper; this was used for much of the total copper production. In the 17th century it was used for the same purposes in Germany and Spain.
Some academics, such as Stéphane Courtois (The Black Book of Communism), Steven Rosefielde (Red Holocaust), and Rudolph Rummel (Death by Government), wrote of mass, excess deaths under Marxist–Leninist regimes. These authors defined the political repression by communists as a "Communist democide", "Communist genocide", "Red Holocaust", or followed the "victims of Communism" narrative. Some of them compared Communism to Nazism and described deaths under Marxist–Leninist regimes (civil wars, deportations, famines, repressions, and wars) as being a direct consequence of Marxism–Leninism. Some of these works, in particular The Black Book of Communism and its 93 or 100 millions figure, are cited by political groups and Members of the European Parliament. Without denying the tragedy of the events, other scholars criticise the interpretation that sees communism as the main culprit as presenting a biased or exaggerated anti-communist narrative. Several academics propose a more nuanced analysis of Marxist–Leninist rule, stating that anti-communist narratives have exaggerated the extent of political repression and censorship in communist states and drawn comparisons with what they see as atrocities that were perpetrated by capitalist countries, particularly during the Cold War. These academics include Mark Aarons, Noam Chomsky, Jodi Dean, Kristen Ghodsee, Seumas Milne, and Michael Parenti. Ghodsee, Nathan J.
=== Synaptic formation and repair === The most-substantiated role for APP is in synaptic formation and repair; its expression is upregulated during neuronal differentiation and after neural injury. Roles in cell signaling, long-term potentiation, and cell adhesion have been proposed and supported by as-yet limited research. In particular, similarities in post-translational processing have invited comparisons to the signaling role of the surface receptor protein Notch. APP knockout mice are viable and have relatively minor phenotypic effects including impaired long-term potentiation and memory loss without general neuron loss. A 2025 mouse study reported that conditional deletion of APP family proteins in excitatory forebrain neurons reduced synaptic localization of the NMDAR subunit GluN1 and suppressed spontaneous cortical and hippocampal neuronal activity, supporting a role for APP family proteins in NMDAR-dependent synaptic and circuit function in vivo. Furthermore, transgenic mice with upregulated APP expression have also been reported to show impaired long-term potentiation. The logical inference is that because Aβ accumulates excessively in Alzheimer's disease its precursor, APP, would be elevated as well. However, neuronal cell bodies contain less APP as a function of their proximity to amyloid plaques. The data indicate that this deficit in APP results from a decline in production rather than an increase in catalysis. Loss of a neuron's APP may affect physiological deficits that contribute to dementia.
== Prognosis == The long-term outlook (prognosis) for people with cold agglutinin disease varies based on many factors including the severity of the condition, the signs and symptoms present in each person and the underlying cause. For example, people with cold agglutinin disease caused by bacterial or viral infections tend to have an excellent prognosis; in these cases, the symptoms typically disappear within 6 months after the infection has resolved. Mild to moderate primary (unknown cause) cold agglutinin disease can also be associated with a good prognosis if excessive exposure to the cold is avoided. Those with cold agglutinin disease caused by HIV infection or certain types of cancer generally have a poor prognosis due to the nature of the underlying condition.
== Names == The adjective Müllerian is written either Müllerian or müllerian, depending on the governing style guide; the derived term with the prefix anti- is then anti-Müllerian, anti-müllerian, or antimüllerian. The Müllerian ducts are named after Johannes Peter Müller. A list of the names that have been used for the antimüllerian hormone is as follows. For the sake of simplicity, this list ignores some orthographic variations; for example, it gives only one row for "Müllerian-inhibiting hormone", although there are four acceptable stylings thereof (capital M or lowercase m, hyphen or space).
Sources: en.wikipedia.org
Infliximab works by binding to TNF, stopping its inflammatory effects. It was initially used for the treatment of Crohn's disease and it became the first FDA approved TNF inhibitor in 1998. Infliximab as well as other TNF inhibitors like adalimumab, certolizumab, and golimumab are currently the most common biologics used in the treatment of both Crohn's disease and ulcerative colitis. The other main categories of biologics that treat IBD are integrin receptor antagonists such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab.
Re2O7 + 17 CO → Re2(CO)10 + 7 CO2 If metal oxides are used carbon dioxide is formed as a reaction product. In the reduction of metal chlorides with carbon monoxide phosgene is formed, as in the preparation of osmium carbonyl chloride from the chloride salts. Carbon monoxide is also suitable for the reduction of sulfides, where carbonyl sulfide is the byproduct.
=== Physiologically based Pharmacokinetics === Physiologically-Based Pharmacokinetic models integrate physiological information to simulate drug behavior in various tissues and organs. These models consider organ-specific blood flow, tissue permeability, and drug properties, facilitating predictions of drug concentration at specific sites. PBPK models are instrumental in understanding complex drug behaviors.
Though originally planned to be presented at a ceremony at the Queen Elizabeth Hall in London, the event was instead presented as a live stream on 2 April 2020 due to concern over the COVID-19 pandemic.
== Function == The transitional epithelium cells stretch readily in order to accommodate fluctuation of volume of the liquid in an organ (the distal part of the urethra becomes non-keratinized stratified squamous epithelium in females; the part that lines the bottom of the tissue is called the basement membrane). Transitional epithelium also functions as a barrier between the lumen, or inside hollow space of the tract that it lines and the bloodstream. To help achieve this, the cells of transitional epithelium are connected by tight junctions, or virtually impenetrable junctions that seal together to the cellular membranes of neighboring cells. This barrier prevents re-absorption of toxic wastes and pathogens by the bloodstream.
Sources: en.wikipedia.org
Fatty acids are also components of the phospholipids that make up the bulk of the lipid bilayers of all cellular membranes. In plants, de novo fatty acid synthesis occurs in the plastids. Many seeds accumulate large reservoirs of seed oils to support germination and early growth of the seedling before it is a net photosynthetic organism. Mitochondrial fatty acid synthesis (mtFAS): Mitochondrial acetyl-CoA is converted to malonyl-CoA by the mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1), in tandem with acyl-CoA synthetase family member 3 (ACSF3), which additionally generates malonyl-CoA from malonate, together providing the extender units for mitochondrial fatty acid synthesis (mtFAS). In response to mitochondrial acetyl-CoA availability, mtFAS builds acyl chains on the matrix-soluble acyl carrier protein (holo-ACP), producing acyl-ACP species with varying chain lengths. These acyl-ACP species are required for the biosynthesis of lipoic acid—a cofactor of key mitochondrial enzyme complexes such as the pyruvate dehydrogenase complex (PDC), the 2-oxoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (OADHC), the branched-chain α-keto acid dehydrogenase complex (BCKDHC), and the glycine cleavage system—as well as for the allosteric activation of the LYRM protein network. Members of this network regulate iron–sulfur cluster biogenesis, assembly of the electron transport chain complexes, and mitochondrial translation, which remains active even under conditions of limited acetyl-CoA availability.
Probable UIP pattern: Predominantly subpleural and basal Often heterogenous distribution Reticular pattern with peripheral traction bronchiectasis or bronchiolectasis There may be mild ground-glass opacity Indeterminate for UIP: Predominantly subpleural and basal Subtle reticular pattern May have mild ground-glass opacity or distortion (“early UIP pattern”) Findings suggestive of another diagnosis, including: Other predominant distribution: Peribronchovascular Perilymphatic Upper or mid-lung Cysts Marked mosaic pattern Predominant ground-glass opacity Profuse lung micronodules Lung nodules, especially centrilobular Consolidation Pleural plaques (indicating asbestosis) Dilated esophagus (indicating connective tissue disease) Distal clavicular erosions (indicating rheumatoid arthritis) Extensive lymph node enlargement Pleural effusion Pleural thickening (indicating connective tissue disease/drugs)
Perineural cysts were first described by Dr. Isadore Tarlov in 1938. While conducting anatomical dissections of 30 human cadavers to study the filum terminale and lower spinal nerve roots, Tarlov identified cystic lesions on the S2 to S5 sacral nerve roots in five specimens, ranging in size from a pinhead to approximately 2 cm. He also reported degenerative changes in the nerve fibers, ganglion cells, and disintegration of myelin sheaths. These observations were published in a paper titled "Perineurial Cysts of the Spinal Nerve Roots (1938)", in which he suggested the possible clinical relevance of the cysts, stating: "One wonders whether they may not be responsible for the discomfort in certain cases of sciatica or nerve root pains, in which any other pathologic basis has been excluded. This awaits further studies with clinical and pathologic correlations." In 1948, Tarlov reported the first clinical case linking sacral perineural cysts to sciatic pain, establishing their potential as a treatable cause of radiculopathy. He described a 42-year-old woman who developed persistent right-sided sciatica following a fall. Although a herniated intervertebral disc was initially diagnosed, surgical exploration revealed a perineural cyst arising from the right S2 sacral nerve root, located under the posterior arch of the sacrum. The lesion was excised along with part of the dorsal root and ganglion. Postoperatively, the patient experienced significant improvement in motor function, pain, and sensation, without complications.
Several studies have determined the potential use of PCSK9 inhibitors in the treatment of hyperlipoproteinemia (commonly called hypercholesterolemia). Furthermore, loss-of-function mutations in the PCSK9 gene result in lower levels of LDL and protection against cardiovascular disease. Drugs can inhibit PCSK9, leading to lowered circulating LDL particle concentrations. Since LDL particle concentrations are thought by many experts to be a driver of cardiovascular disease like heart attacks, it is plausible that these drugs may also reduce the risk of such diseases. Clinical studies, including phase III clinical trials, are now underway to describe the effect of PCSK9 inhibition on cardiovascular disease, and the safety and efficacy profile of the drugs. Among those inhibitors under development in December 2013 were the antibodies alirocumab, evolocumab, 1D05-IgG2 (Merck), RG-7652 and LY3015014, as well as the RNAi therapeutic inclisiran. PCSK9 inhibitors are promising therapeutics for the treatment of people who exhibit statin intolerance, or as a way to bypass frequent dosage of statins for higher LDL concentration reduction. A review published in 2015 concluded that these agents, when used in patients with high LDL-particle concentrations (thus at greatly elevated risk for cardiovascular disease) seem to be safe and effective at reducing all-cause mortality, cardiovascular mortality, and heart attacks.
Residents of the district have developed their own unique sense of humour, as evidenced by Myers, whose Wayne's World character was inspired by growing up in the area. Other Scarborough natives include Lilly Singh, Eric McCormack (Will & Grace), John Candy (Second City, SCTV), musical group Barenaked Ladies and singer Abel Tesfaye known as the Weeknd. Actor Jim Carrey also lived in Scarborough during his teen years. Scarborough has also been the home of prominent hip hop artists and producers, including Maestro Fresh Wes, Choclair, Boi-1da, Nineteen85, Kardinal Offishall, Saukrates, David Strickland and the group BrassMunk. According to the list of largest shopping malls in Canada, the Scarborough Town Centre is the fifth-largest in the country and the fourth-largest in the GTA. It is located next to the Scarborough Civic Centre, Albert Campbell Square, and Consilium Place. This area was developed as a city centre for the former City of Scarborough government. The Scarborough Walk of Fame is also located in the Town Centre, consisting of plaques embedded in the floor to honour notable residents, past and current. The inaugural inductees included National Basketball Association player Jamaal Magloire, Olympic gold medalist Vicky Sunohara, and eight prominent residents who contributed to advances in medicine, arts, and the community.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.